Study: Kidney biopsy cores are safe to obtain in patients with diabetes
Click Here to Manage Email Alerts
Obtaining research kidney biopsy cores in patients with diabetes was safe with no clear evidence of a negative impact, according to findings from a recently published study.
“The heterogeneity of diabetic kidney disease and predominant study of blood and urine rather than direct analysis of kidney tissue are both barriers to identifying biomarkers and novel therapeutic targets for progressive disease,” Jonathan J. Hogan, MD, from the Perelman School of Medicine, University of Pennsylvania, and colleagues wrote. “Data are lacking regarding the feasibility and safety of obtaining research kidney biopsy cores.”
In a multicenter, longitudinal, observational cohort study, researchers in the Transforming in Diabetic Nephropathy (TRIDENT) study enrolled 160 patients with diabetes who underwent clinically indicated kidney biopsies from January 2017 to May 2019. A research biopsy core was successfully obtained in 90% of patients.
Study results reported that of 160 patients, 7% experienced biopsy-related complications. Researchers found 2% of patients required blood transfusion, 4% developed a hematoma greater than 5 cm, 2% experienced gross hematuria and 4% required a prolonged hospital stay. Of the patients with a successfully obtained biopsy core (144 patients), 6% experienced biopsy-related complications. None of the study patients required surgical or radiologic intervention.
Investigators noted the overall outcome of the study proved there was no clear evidence of a negative impact from obtaining research kidney biopsy cores.
“This interim analysis of the TRIDENT study is the rst report describing the feasibility and safety of obtaining research tissue during clinically indicated kidney biopsies,” Hogan and colleagues wrote. “This data will help potentiate the safety of obtaining kidney tissue for research, ultimately improving care for patients with diabetic kidney disease.” – by Kate Burba
Disclosures: Hogan reports grants from Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline and Regeneron Pharmaceuticals during the conduct of the study; personal fees from Retrophin, Dimerix, Zyversa and GSK; and other fees from Calliditas, Omeros and Achillion. Please see the study for all other authors’ disclosures.
Collapse
Hogan JJ, et al. CJASN. 2020;doi:10.2215/CJN.13061019.
Read more about
Click Here to Manage Email Alerts